|
Factor (mean (range))
|
All patients (N = 28)
|
No LGE (N = 19)
|
LGE (N = 9)
|
p-value
|
|---|
|
Dmax Heart EQD2 (Gy)
|
50.9 (6.2–108.0)
|
46.1 (6.2–82.6)
|
60.8 (40.8–108.0)
|
0.16
|
|
Dmean Heart EQD2 (Gy)
|
8.2 (1.0–35.7)
|
8.8 (1.0–35.7)
|
6.8 (1.8–21.8)
|
0.57
|
|
Dmax LV EQD2 (Gy)
|
34.0 (0.2–94.7)
|
29.4 (0.2–74.7)
|
43.8 (13.6–94.7)
|
0.17
|
|
Dmean LV EQD2 (Gy)
|
8.2 (0.1–34.4)
|
8.4 (0.1–30.0)
|
7.6 (1.4–34.4)
|
0.84
|
|
Heart V5Gy (%)
|
48.5 (10–97)
|
49.3 (10–97)
|
46.8 (13–96)
|
0.85
|
|
Heart V30Gy (%)
|
10.8 (0–69)
|
11.0 (0–66)
|
10.5 (0–44)
|
0.94
|
|
Heart V40Gy (%)
|
7.6 (0–66)
|
8.1 (0–66)
|
6.7 (0–33)
|
0.83
|
|
Heart V50Gy (%)
|
5.1 (0–59)
|
5.8 (0–59.0)
|
3.4 (0–23)
|
0.65
|
|
LV V5Gy (%)
|
40.1 (0–100)
|
37.3 (0–100)
|
45.1 (18.5–100)
|
0.61
|
|
LV V30Gy (%)
|
10.7 (0–71.8)
|
10.7 (0–65.1)
|
10.7 (0–71.8)
|
0.99
|
|
LV V40Gy (%)
|
7.7 (0–55.5)
|
7.8 (0–55.5)
|
7.4 (0–53.1)
|
0.95
|
|
LV V50Gy (%)
|
5.1 (0–48.8)
|
5.6 (0–48.8)
|
4.3 (0–36.4)
|
0.81
|
|
T1 mapping values (ms)
|
1009 (933–1117)
|
997 (933–1067)
|
1033 (967–1117)
|
0.054
|
- *Dmax maximum dose, Dmean mean dose, EQD2 equivalent dose in 2 Gy fractions, Gy Gray, LGE late gadolinium enhancement, LV left ventricle, ms milliseconds, Vx volume in % receiving ≥ dose x in Gy. P-values reported for significance testing among patients with and without LGE
